A New Test Developed In The UK May Lead To Earlier Diagnosis Of Osteoarthritis
April 26, 2010
Researchers at King's College London's Department of Twin Research and Genetic Epidemiology, based at St Thomas' Hospital, have discovered new ways of measuring biological markers in the blood that could be used to make an earlier diagnosis of osteoarthritis, the condition that primarily affects the joints in the knees, hips and small joints of the hands, but can strike almost any joint. The new biochemical test called metabolomics allows the scientists to test for 163 chemical signals at the same time from a single blood sample. These chemical signals are intermediate products of the metabolism of human cells and their 26,000 metabolite ratios represent the rate of the chemical reactions in the human body. The team first studied 123 women with osteoarthritis of the knee and 299 healthy women from the Twins UK register, comparing the difference in the metabolites and the 26,000 metabolite ratios between the two groups. They found that 14 metabolite ratios were significantly associated with osteoarthritis. The team then tested these signals to see if they were replicated in an independent sample consisting of 76 women with knee arthritis and 100 healthy women. Two ratios were successfully confirmed in the replication sample. Dr Guangju Zhai, lead author on the paper published in the journal Annals of Rheumatic Diseases, said, "Osteoarthritis affects an estimated 8.5 million people in the UK and one of its main characteristics is damage to cartilage, the strong smooth muscle that lines the bones and allows joints to move easily and without friction. The search for biomarkers, or traits, which can be used to measure or indicate the effects or progress of a condition is a hugely exciting area of clinical research. The two novel metabolic biomarkers found through our study could indicate increased cartilage breakdown and we now want to study these mechanisms in more detail." Professor Tim Spector, senior author of the paper added, "Ours is the first study using a metabolomics approach to identify novel metabolic biomarkers for osteoarthritis. We hope that further research will lead to these two metabolite ratios being adopted into clinical practice, enabling doctors to diagnose the condition, or identify that osteoarthritis is developing, earlier. Our study also shows the enormous clinical potential of metabolomics, and we hope in future that they could be used to monitor the effectiveness of treatments. At the moment we relay on x-rays and scans, and our dependence on these methods is a major obstacle to the development of new drugs for osteoarthritis."
Stay connected with Parentgiving.
New subscribers will save 10% on your first order!*
*New subscribers only. This coupon cannot be combined with other offers, used on Dry Direct
orders or used on Golden Technologies, Pride Mobility or Joerns products. Maximum savings of $75. Some restrictions